What is William Blair’s Estimate for SPRY FY2024 Earnings?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at William Blair lifted their FY2024 earnings estimates for shares of ARS Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of ($0.16) per share for the year, up from their previous estimate of ($0.17). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.58) per share. William Blair also issued estimates for ARS Pharmaceuticals’ FY2025 earnings at ($0.44) EPS.

Other research analysts have also recently issued reports about the company. Leerink Partners upped their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Raymond James upped their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $26.00.

ARS Pharmaceuticals Trading Up 0.5 %

Shares of SPRY opened at $13.55 on Thursday. The firm has a 50-day simple moving average of $12.46 and a two-hundred day simple moving average of $12.93. ARS Pharmaceuticals has a 1-year low of $6.13 and a 1-year high of $18.51.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SPRY. nVerses Capital LLC acquired a new stake in shares of ARS Pharmaceuticals during the third quarter worth about $30,000. Quarry LP purchased a new stake in ARS Pharmaceuticals during the 3rd quarter valued at approximately $174,000. The Manufacturers Life Insurance Company acquired a new stake in ARS Pharmaceuticals during the 2nd quarter worth approximately $180,000. TFG Advisers LLC purchased a new position in shares of ARS Pharmaceuticals in the 3rd quarter valued at approximately $180,000. Finally, Stifel Financial Corp acquired a new position in shares of ARS Pharmaceuticals in the third quarter valued at approximately $199,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Insider Buying and Selling

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $18.04, for a total value of $9,533,346.24. Following the transaction, the insider now directly owns 5,274,735 shares in the company, valued at $95,156,219.40. This represents a 9.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Laura Shawver sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $11.10, for a total transaction of $555,000.00. Following the sale, the director now owns 210,346 shares of the company’s stock, valued at $2,334,840.60. This represents a 19.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,095,558 shares of company stock worth $16,853,686 over the last 90 days. 40.10% of the stock is owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.